The Valley Desk

NCT02766335 · Interventional trial

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Overall registry status Completed

Phase 2 · Phase 3

Conditions Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov